This segment brings together two essential threads — the broader context of lorlatinib's remarkable durability relative to ...

This segment addresses one of the most practically important aspects of lorlatinib therapy — its distinct and manageable ...

Kutscher says MDVIP is expanding into specialty care and eyeing pediatrics. Your browser does not support the audio element.

Positive symptoms correlated with more negative sentiment and longer utterances, whereas negative symptoms aligned with ...

FDA approved veligrotug-vvze for TED regardless of activity or duration, using a 12-week course of five IV infusions administered every three weeks. Pivotal THRIVE/THRIVE-2 trials met primary and all ...

Zanubrutinib plus rituximab demonstrated a clinically meaningful progression-free survival advantage over bendamustine plus rituximab in previously untreated MCL, with a 43% risk reduction for ...

In SYNCHRONIZE-MASLD (n=218), 84.2% on weekly survodutide 6.0 mg achieved ≥30% relative liver fat reduction versus 24.3% with placebo at week 48. Liver fat normalization occurred in ~61% of ...

Financial sustainability and innovation are interdependent, as clinician-led contracting strategies that improve outcomes generate savings that fund further innovation. Balancing innovation and ...

Cohorts included 1,653 AL, 1,055 ATTRwt-CM, and 59 dual-diagnosis patients; only 53%–66% had any relevant test documented, and just 40%–49% had AL-specific workups. Complete monoclonal protein testing ...

Sponsored by Esperion. Newsletter Get the latest industry news, event updates and more from Managed Healthcare Executive.

Reconstructed IPD meta-analysis showed chemoimmunotherapy improved OS and PFS versus PD-(L)1 monotherapy within PD-L1–high disease, with consistent findings across multiple analytic approaches and ...

An in-depth look at multiple myeloma treatment with a focus on bispecific antibodies. A special Managed Healthcare Executive supplement on the current treatment of multiple myeloma with an emphasis on ...